MyoKardia Reports Third Quarter 2018 Financial Results
07 nov. 2018 16h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
07 nov. 2018 08h01 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
05 nov. 2018 08h00 HE
|
MyoKardia, Inc.
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of Mavacamten’s Effect on...
MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
05 nov. 2018 08h00 HE
|
MyoKardia, Inc.
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) MyoKardia...
MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day
30 oct. 2018 07h30 HE
|
MyoKardia, Inc.
Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy Volunteers Presented;...
MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe
25 oct. 2018 00h00 HE
|
MyoKardia, Inc.
First-of-its-kind Digital Platform for HCM Patients Intended to Provide a Powerful Patient Resource to Improve Disease Understanding and Deepen Patient Engagement and Advocacy SOUTH SAN FRANCISCO,...
MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy
24 oct. 2018 16h30 HE
|
MyoKardia, Inc.
Key Remaining Study in Registration Program for oHCM Enables Assessment of Mavacamten’s Potential for Disease Modification SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- MyoKardia,...
MyoKardia to Host R&D Day on October 30, 2018
22 oct. 2018 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia to Present at the 2018 Cantor Global Healthcare Conference
24 sept. 2018 08h01 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia to Present at Two Upcoming Investor Conferences in September
29 août 2018 16h01 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...